Home / Fact Sheet
Home / Fact Sheet
Fact Sheet
Avesthagen was founded as a grid of verticals of biodiversity and horizontals of “omics” platforms. It has grown into an internationally recognised pioneer by using systems-biology to facilitate Scientific Discovery & Technology Development, with the aim of delivering innovative products and technologies for Healthcare, Wellness and Agriculture. The convergence of food, pharma and population genetics delivered by the Company offers a unique pathway to the understanding of chronic disease and the wider role of health-related products during treatment. Additional insights and outcomes from this novel approach deliver Wellness, Nutrition, Energy and Environment solutions impacting wider global issues.
The Company is accelerating its core genomics programme and the commercialisation of its current and pipeline, products and technologies. Avesthagen is creating India’s Genomics and Precision Medicine powerhouse.
The AVESTAGENOME Project® is a subsidiary focused on the systems biology study of the endogamous Parsi community diaspora with focus on Cancers, Rare Disorders and Neurodegenerative Conditions. The company’s important and valuable genomics BIObank and database is at the confluence of disease identification, clinical treatment and well-being with its goal to secure better patient outcomes at an acceptable cost proposition to developed and developing healthcare countries.
Avesthagen will develop and commercialise new products and technologies through its subsidiaries
4,500 samples of Edogamous Parsi population Whole Genome sequencing: Identification of the novel genome makers and druggable targets.
Go-To-Market: Co-development with Academic and commercial partenrs, Licensing of early research biomakers and drug targets.
Scientifically validated Botanical BioActives for health and wellness. AvesthaDHA® from vegetarian Microalgae source Avesta Good Earth Functional & Medical foods.
Go-To-Market: Online & Direct retail of the above products through digital marketing , in store, sales, B2B, and B2C.
Environment Adjusted Crop® Technology
– Salinity FIT
– Drought FIT
– Nutrition FIT
– Hydrid FIT
– Biofuels
Go-To-Market: Co-development partnerships with MNC’s Fee for Seed Industry Services, Licensing of Patents.
AVDESP (Biosimilar for Diabetes)
AVENT (Biosmiliar for Rheumatoid Arthritis)
AVEBEV, AVETUX, AVPLASE, AVCEPTIN, AVCADE and AVCET
Go-To-Market: Pure licensing approach, JV’s and Partnerships.